Cycle on May 24, 2026

I will call `list_threads` to check the current open threads for the topic `019e46ac-88a3-731f-aeee-a2d9443452d6` so we can see what specific lines of inquiry the user or previous cycles have flagged for follow-up.

I will search the web for information regarding the "Medicare GLP-1 Bridge program" to see what recent announcements or guidelines have been released as we approach its July 1, 2026 launch date.

I will search for newer clinical trial results, pipeline updates, and corporate actions from Eli Lilly and Novo Nordisk, or competitors like Kailera, Viking Therapeutics, Roche, Pfizer, etc., in May 2026. This will help us build a comprehensive update on the clinical pipeline, approvals, health insurance trends, and device impacts. Let's do a few searches.

Let's look at the Prime Therapeutics GLP-1 Pipeline Update from May 2026. This page could contain concrete, up-to-date data for May 2026. Let's fetch it. I will fetch `https://www.primetherapeutics.com/glp-1-pipeline-update-may-2026`.

Wow, this is an incredibly rich and up-to-date document from Prime Therapeutics dated May 22, 2026. It contains specific details on: 1. **Wegovy HD (7.2 mg)** FDA approval on March 19, 2026, demonstrating a mean weight loss of 20.7% at 72 weeks (STEP UP trial), approved using the Commissioner's National Priority Voucher (CNPV) pilot. 2. **Eli Lilly's orforglipron (Foundayo)** oral nonpeptide GLP-1 FDA approval for obesity on April 1, 2026, demonstrating 12.4% mean weight loss at 72 weeks (ATTAIN-1 trial), also under CNPV. Available in multiple strengths. 3. **Cagrilintide/semaglutide (CagriSema)** combination from Novo Nordisk awaiting FDA decision in December 2026, showing 22.7% weight loss in REDEFINE-1. 4. **Mounjaro (tirzepatide)** CV risk reduction (MACE) FDA decision in mid-2026 (SURPASS CVOT trial). 5. **Ozempic oral tablets** (formerly Rybelsus) proprietary name change in February 2026 for 1.5-mg, 4-mg, and 9-mg formulations, providing improved bioavailability. Available on May 4, 2026. 6. **Autoimmune disease trials**: Tirzepatide in Phase 3 combination with Taltz (ixekizumab) for plaque psoriasis / psoriatic arthritis, expected to complete first half of 2026; tirzepatide + Omvoh (mirikizumab) for ulcerative colitis / Crohn's. 7. **Alcohol-use disorders (AUD)**: Semaglutide Phase 2 SEMALCO trial results, plus a Phase 3 CRAVE trial in US veterans. Other drugs in Phase 2 for AUD. 8. **Generics**: Liraglutide (Victoza) generics available; Teva launched first generic of Saxenda (weight loss) in August 2025; additional Saxenda generics in Feb 2026; Dulaglutide (Trulicity) generic potentially late 2027. This is exactly the type of hard evidence we need. Let's research more on the Medicare GLP-1 Bridge program guidelines, pharmacy uptake, and physician attestation to answer the open thread. Let's do a search.

Let's fetch the Reed Smith article on "CMS Provides Details for Medicare GLP-1 Bridge Coverage for Eligible Part D Beneficiaries". It seems to have detailed, concrete legal and regulatory facts about the program. Let's fetch `https://www.reedsmith.com/our-insights/blogs/health-industry-washington-watch/102mm7i/cms-provides-details-for-medicare-glp-1-bridge-coverage-for-eligible-part-d-ben/`.

This Reed Smith article is extremely useful. Let's look at another article that mentions that the Medicare GLP-1 Bridge program has been extended through December 31, 2027. Wait, let's search for "CMS Extends Medicare's Short-Term Bridge Program for GLP-1" or "obesitymedicine.org/blog/cms-announces-changes-to-medicare-coverage-of-glp-1-medications-for-2027". Let's fetch that page or do a search. Let's do a search for details on the extension of the Bridge program through 2027.

Let's check the details of this extension and the delay of the BALANCE model. This is critical for an investor. Let's search for "CMS Extends Medicare GLP-1 Bridge, Delays BALANCE Model in Part D" or fetch the KFF article "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid" or the Avalere Health article "Bridging the Gap: The Future of GLP-1 Coverage in Part D". Let's fetch the KFF article or Avalere article. Let's do a search to see which one we can fetch. Let's fetch `https://advisory.avalerehealth.com/insights/bridging-the-gap-the-future-of-glp-1-coverage-in-part-d`.

This is an outstanding, highly detailed regulatory update. Let's summarize the key facts for an investor: 1. **BALANCE Model Delayed & GLP-1 Bridge Extended**: On April 21, 2026, CMS announced that it would delay the implementation of the Medicare Part D portion of the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model (originally set to launch in 2027) and extend the Medicare GLP-1 Bridge demonstration through December 31, 2027. 2. **Bridge Program Design**: - Runs from July 1, 2026, through December 31, 2027 (originally scheduled for July 1 to December 31, 2026). - Operates entirely outside the standard Part D benefit structure. - Beneficiaries pay a flat $50 copay per monthly supply. - This $50 copay does *not* count toward the Part D deductible or out-of-pocket (OOP) limit, and plan sponsors bear zero liability for these drugs. - Participating manufacturers (Novo Nordisk and Eli Lilly) will provide eligible drugs (Wegovy and Zepbound) at a net price of $245 per monthly supply. (Manufacturers pay rebates to CMS equal to the difference between WAC and $245). - Administrative functions (prior authorization, claims adjudication, pharmacy payment) will be handled by a "single central processor" contractor, not Part D plans or their PBMs. - Specific Bank Identification Number (BIN) and Processor Control Number (PCN) for the Bridge Program: `028918 MEDDGLP1BR`. - Pharmacy reimbursement will be "no lower than" Wholesale Acquisition Cost (WAC) less the $50 copay, plus an unspecified dispensing fee and sales tax. 3. **Why BALANCE was delayed**: - Plan bids for 2027 are due June 1, 2026. Because GLP-1s for weight loss have never been covered under Part D, there is no historical claims data to estimate utilization. Plans faced massive financial uncertainty in pricing competitive bids. - Risk of adverse selection: plans that opted into BALANCE could face a higher concentration of beneficiaries taking expensive GLP-1s. - The Bridge extension gives CMS and plans 18 months of real-world claims and utilization data before transitioning to a permanent model. 4. **Coverage overlap**: - If a GLP-1 is "coverable" under Part D (e.g. Wegovy for MACE reduction in patients with CV disease, or Zepbound for sleep apnea), the patient does *not* qualify for the Bridge Program. They must access it through their Part D plan. This creates a critical administrative distinction that pharmacies and physicians must navigate. Let's do some more research on other elements of the topic brief: - Competitive landscape / pipeline updates (e.g., Viking Therapeutics, Roche, Kailera, etc.) - Health insurance coverage and pricing (e.g., Novo Nordisk braces for price cuts, Supreme Court Medicare pricing decision mentioned in the May 22 summary, let's search for details) - Medical devices (bariatric surgery, CGM - Dexcom, Abbott) - Consumer adoption trends Let's search for Viking Therapeutics VK2735 and other pipeline competitors in May 2026.

Wow, look at this! There is a press release from Viking Therapeutics dated May 12, 2026: "Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026". This is incredibly fresh and relevant! Let's fetch `https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026`. This is a direct source. Let's read it.

This is a phenomenal find. Viking Therapeutics (NASDAQ: VKTX) presented data at the European Congress on Obesity (ECO) 2026 on May 12, 2026. The 13-week Phase 2 VENTURE-Oral study of VK2735 (oral tablet) demonstrated: - High dose (120 mg) achieved a mean body weight reduction of up to 12.2% (26.6 lbs) from baseline at 13 weeks. Or placebo-adjusted mean percent change was 10.9%. - Dose-dependent, progressive weight loss starting early (Week 1) with no plateau. - Tolerability was favorable (98% of TEAEs mild/moderate, GI events diminished over time). - Plans to move oral VK2735 into Phase 3 development later this year (2026). - Subcutaneous formulation is in the ongoing Phase 3 VANQUISH registration program (VANQUISH-1 and VANQUISH-2). Let's search for Roche's obesity pipeline updates or other competitors like Kaiser/Kailera Therapeutics or Pfizer. Let's do a search on Roche's GLP-1 or obesity pipeline in 2026.

Let's check the BioPharma Dive article "Roche, trailing in obesity, showcases new data for GLP-1 shot" from Jan/Feb or May 2026. Wait, let's search for "Roche obesity drug CT-388 Phase 2 data" or fetch the Roche media release from Jan 27, 2026. Let's search for "Roche med-cor-2026-01-27" or fetch `https://www.roche.com/media/releases/med-cor-2026-01-27`. That is a direct source. Let's do a search for the exact title.

Let's fetch `https://www.roche.com/media/releases/med-cor-2026-01-27` to get the exact data for Roche's CT-388. This will be highly valuable for the competitive landscape.

This is another fantastic piece of concrete data. Roche's once-weekly subcutaneous injectable dual GLP-1/GIP receptor agonist **CT-388** achieved a statistically significant placebo-adjusted weight loss of **22.5%** at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss plateau. - 54% of participants on the 24 mg dose achieved resolution of obesity (BMI < 30 kg/m2). - At week 48, 95.7% of treated participants achieved ≥5% weight loss, and 26.1% achieved ≥30%. - 73% of pre-diabetic participants treated with CT-388 achieved normal blood glucose levels. - Phase III clinical trial program (Enith1 and Enith2) expected to start in Q1 2026. - CT-388 is also considered a combination asset for **petrelintide** (Roche's amylin analogue). Let's look at medical device impacts. The prompt mentions "impact on medical device companies like bariatric surgery and diabetes monitoring". Let's search for "bariatric surgery volumes GLP-1 2026" or "Dexcom Abbott CGM sales GLP-1 impact 2026". Let's do some searches.

Look at this! There are studies and articles published in 2026 showing exactly what is happening to bariatric surgery. Let's do a search for the Mass General Brigham study: "Study Finds Bariatric Surgery Declined with Rise in GLP-1 Drugs to...". Let's search for that study or fetch its details. Let's do a search.

Ah, the Mass General Brigham study was published in late 2024 / early 2025. It shows that bariatric surgery declined with the rise of GLP-1 drugs. Let's fetch `https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/study-finds-bariatric-surgery-declined-with-rise-in-glp-1-drugs` to get the actual findings and statistics. This will give us solid, concrete figures.

Excellent. This provides a very clear, concrete statistic on the decline of bariatric surgery: - GLP-1 RA use increased 105.7% from the last six months of 2022 to the last six months of 2023 (from 2.16 to 4.43 patients per 1,000 patients). - Bariatric surgery decreased 8.7% during the same period (from 0.23 to 0.21 patients per 1,000 patients). - "Metabolic bariatric surgery and GLP-1 RAs are both effective interventions for patients with obesity, yet less than 6% of patients in our study received either form of treatment." Let's do a search on Dexcom and Abbott CGM sales and GLP-1 impact in 2026. This will give us a complete picture of the medical devices aspect.

Let's check Dexcom's Q1 2026 earnings or recent reports to see if there is any mention of GLP-1 users. Let's do a search.

Ah! The web search budget is exhausted. No problem. Let's look closely at what we have. Wait, let's look at the SEC.gov document we found earlier for Dexcom or Abbott or Eli Lilly. Let's see what we can find. Or let's use the information we already have. Wait, we have: 1. **The Medicare GLP-1 Bridge program launch (July 1, 2026)** and its extension to Dec 31, 2027, as well as the delay of the BALANCE model. This is a massive, incredibly detailed regulatory update. Let's make sure we write a note summarizing this. We can reuse the slug of the thread or a fresh slug if it's a new finding, but wait, the open thread title is: "Track the July 1, 2026 launch and initial patient volume of the Medicare GLP-1 Bridge program" (ID `019e53de-db5a-77a8-b3d2-d534444016e5`). Let's see if we should resolve this thread or write a note and then resolve/update it. Wait! The thread describes: "The Medicare GLP-1 Bridge program launches on July 1, 2026, offering flat $50 copays for Wegovy, Foundayo, and Zepbound KwikPen to eligible high-risk seniors. A future cycle should track the operational rollout, pharmacy uptake, physician attestation rates, state Medicaid state plans, and the initial volume/expenditure impact of this program on Medicare's budget." Our new findings show a major shift: CMS has officially extended the Bridge program and delayed the permanent BALANCE model. This is a massive update that directly impacts this thread. We can write a note about this and resolve this thread, or keep a new thread open to track the actual launch on July 1, 2026, and initial patient volumes, since today is May 24, 2026, and the launch is still in the future (July 1, 2026). Wait, let's write a note on the Medicare GLP-1 Bridge program extension and the BALANCE model delay first. Let's look at the other findings we have: 1. **Viking Therapeutics (VKTX) Phase 2 Oral VENTURE Data (May 2026)**: - Oral VK2735 achieved a mean reduction of 12.2% (26.6 lbs) from baseline after 13 weeks of daily dosing (120 mg dose). - Dose-dependent, progressive weight loss without a plateau. - 80% achieved ≥10% weight loss vs 5% for placebo. - Extremely well tolerated, 98% of TEAEs mild/moderate. - Moving oral VK2735 into Phase 3 registration studies in late 2026. - Injectable formulation is in Phase 3 VANQUISH-1 and VANQUISH-2 registration studies. This is a major pipeline update that refines the competitive landscape. 2. **Roche's CT-388 Phase 2 Trial Results (January 2026)**: - Once-weekly subcutaneous dual GLP-1/GIP receptor agonist CT-388 achieved 22.5% placebo-adjusted weight loss at 48 weeks (24 mg dose). - 54% of participants achieved resolution of obesity (BMI < 30). - 26.1% achieved ≥30% weight loss. - Initiating Phase 3 Enith1 and Enith2 trials in Q1 2026. - Biased signaling minimizes receptor internalization and desensitization. 3. **Prime Therapeutics GLP-1 Pipeline Update (May 22, 2026)**: - **Wegovy HD (7.2 mg)** once-weekly SC injection approved on March 19, 2026, for weight loss. Demonstrated 20.7% weight loss at 72 weeks (STEP UP trial), approved under the FDA's Commissioner's National Priority Voucher (CNPV) pilot. - **Foundayo (orforglipron)** once-daily oral nonpeptide GLP-1 approved on April 1, 2026, for obesity. Demonstrated 12.4% weight loss at 72 weeks (ATTAIN-1 trial), also under CNPV. It can be taken at any time of day with no food/water restrictions. - **CagriSema (cagrilintide/semaglutide)** FDA decision expected in December 2026. REDEFINE-1 trial showed 22.7% mean weight loss at 68 weeks. - **Ozempic Tablets**: Rybelsus tablets renamed to Ozempic oral tablets in February 2026 (1.5-mg, 4-mg, 9-mg) with improved bioavailability and launched on May 4, 2026. - **Autoimmune disorders**: Tirzepatide combined with Taltz (ixekizumab) in Phase 3 for plaque psoriasis/psoriatic arthritis (completing first half of 2026); tirzepatide + Omvoh (mirikizumab) in Phase 3 for ulcerative colitis/Crohn's (completing 2028). - **Alcohol Use Disorder (AUD)**: Semaglutide Phase 2 SEMALCO trial showed 41.1% reduction in heavy drinking days vs 26.4% for placebo; Phase 3 CRAVE trial in US veterans announced (completing 2028). 4. **Bariatric Surgery Decline**: - Mass General Brigham study published in late 2024 / early 2025 showed that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 (105.7% increase), while rates of bariatric surgery dropped by 8.7%. - Suggests a long-term shift from surgical to pharmacological management, though less than 6% of eligible patients with obesity received either form of treatment. Let's organize our notes. Wait! We have several prior findings: - `cycle-summary-2026-05-20` (GLP-1 Research Cycle Summary — May 20, 2026) - `cycle-summary-2026-05-22` (GLP-1 Research Cycle Summary — May 22, 2026) - `oral-obesity-pills-approved-medicare-glp1-bridge` (The Rise of Oral Obesity Pills: FDA Approves Lilly's Foundayo™ alongside Medicare's New GLP-1 Bridge Program) - `kailera-therapeutics-ipo-glp1-challenger` (Kailera Therapeutics IPO: $625M Raise, First New GLP-1 Public Challenger) - `glp1-restaurant-industry-impact-consumer-spending` (GLP-1 Drugs Reshaping Restaurant Industry: 12% of US Adults on Therapy) Wait, the prior finding `oral-obesity-pills-approved-medicare-glp1-bridge` covers the oral obesity pills and the Medicare GLP-1 Bridge program. We can update this finding to include the new May 2026 updates: - The official FDA approval date of Foundayo (orforglipron) on April 1, 2026, and its clinical details (ATTAIN-1 trial, 12.4% weight loss, oral nonpeptide taken anytime without food/water restrictions). - The official FDA approval of Wegovy HD (7.2 mg) on March 19, 2026, under the CNPV pilot, demonstrating 20.7% weight loss (STEP UP trial). - The Rybelsus name change to Ozempic oral tablets in Feb 2026, launched May 4, 2026, with improved bioavailability. - The major regulatory shift on April 21, 2026: CMS delayed the Part D portion of the BALANCE model and extended the Medicare GLP-1 Bridge program through December 31, 2027. - Detailed Bridge program mechanics (the $50 copay, $245 monthly net manufacturer price, single central processor, BIN/PCN, WAC reimbursement to pharmacies). Let's look at what is in `oral-obesity-pills-approved-medicare-glp1-bridge`. Since we don't have its exact text, we can write a highly comprehensive update and reuse the slug `oral-obesity-pills-approved-medicare-glp1-bridge` to overwrite or append to it. Wait, the instructions say: "When writing a finding that refines one of the above, reuse its slug to update. Otherwise pick a fresh slug." Let's see if we should write a dedicated finding for the Medicare GLP-1 Bridge program and BALANCE model delay, as it's a massive regulatory shift, or update `oral-obesity-pills-approved-medicare-glp1-bridge` with all these details. Let's write a dedicated update for `oral-obesity-pills-approved-medicare-glp1-bridge` which covers both oral pills (Foundayo, Wegovy HD, Ozempic tablets) and the Medicare GLP-1 Bridge program extension/BALANCE delay. Wait, let's also write a new finding for the competitive pipeline: Viking's VENTURE-Oral Phase 2 results (May 12, 2026) and Roche's CT-388 Phase 2 results (January 2026). Let's call it `glp1-competitive-pipeline-viking-roche-updates` or similar, as a fresh slug. And we can write another finding for the bariatric surgery impact: `glp1-bariatric-surgery-decline-device-impact`. And we can write a cycle summary for May 24, 2026: `cycle-summary-2026-05-24`. Let's check if there are any specific guidelines on how to format the findings. "Every substantive finding must: - name and link the actual thing (the story, article, paper, or page that was posted/published) — not just "the discussion", - carry 1-2 REPRESENTATIVE VERBATIM QUOTES, copied exactly, each kept with the link it came from (an HN comment permalink, the article URL, etc.), - then say what it means." No YAML frontmatter. First heading is "# <Title for this finding>". Ends with "## Sources". Let's draft the first finding: **The Rise of Oral Obesity Pills and the Expanded Medicare GLP-1 Bridge Program** (slug: `oral-obesity-pills-approved-medicare-glp1-bridge`). Let's make sure it has the exact quotes and links. Let's review our sources for the first finding: 1. Prime Therapeutics GLP-1 Pipeline Update (May 22, 2026): - Link: `https://www.primetherapeutics.com/glp-1-pipeline-update-may-2026` - Verbatim quote: "On April 1, 2026, the FDA approved orforglipron (Foundayo) by Eli Lilly — for adults with obesity or overweight who also have weight-related medical problems — to reduce excess body weight and maintain weight reduction long term... continuous use of the highest dose of Foundayo led to an average weight loss of 12.4% (27.3 pounds) after 72 weeks" - Verbatim quote: "On March 19, 2026, the FDA approved a new, high-dose semaglutide (Wegovy HD) injection (7.2 mg)... In the STEP UP clinical trial, the 7.2-mg dose demonstrated a mean weight loss of 20.7% at 72 weeks" - Verbatim quote: "In February 2026, the FDA approved Ozempic as the new proprietary name for the 1.5-mg, 4-mg and 9-mg oral semaglutide formulations for adults with T2DM. Ozempic tablets provide improved bioavailability, enabling them to deliver a therapeutic effect comparable to the original 3-mg, 7-mg and 14-mg oral semaglutide doses marketed as Rybelsus." 2. Reed Smith's CMS Provides Details for “Medicare GLP-1 Bridge” Coverage (March 9, 2026): - Link: `https://www.reedsmith.com/our-insights/blogs/health-industry-washington-watch/102mm7i/cms-provides-details-for-medicare-glp-1-bridge-coverage-for-eligible-part-d-ben/` - Verbatim quote: "Part D plan sponsors will not be directly involved in the Bridge Program. Instead, CMS will use a 'single central processor' for administrative functions, including prior authorization, claims adjudication, and pharmacy payment." - Verbatim quote: "The central processor will reimburse pharmacies at 'no lower than' the wholesale acquisition cost (WAC) of the drug, less the $50 copay, plus a dispensing fee, and, where applicable, sales tax." - Verbatim quote: "CMS will pay a net price of $245 per monthly supply for GLP-1s under the Bridge Program." 3. Avalere Health's Bridging the Gap: The Future of GLP-1 Coverage in Part D: - Link: `https://advisory.avalerehealth.com/insights/bridging-the-gap-the-future-of-glp-1-coverage-in-part-d` - Verbatim quote: "On April 21, the Centers for Medicare & Medicaid Services (CMS) announced that it would delay the implementation of the Medicare Part D portion of Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model and extend the Medicare GLP-1 Bridge demonstration through December 31, 2027." - Verbatim quote: "Because GLP-1s for weight loss have never been covered under Part D, there is no existing claims data to reliably estimate how many Medicare beneficiaries may qualify under the model and its impact on uptake and utilization of GLP-1s. Without this data to anchor projections, plan sponsors faced considerable uncertainty in accurately estimating their expected drug spend, pricing competitive bids, and setting appropriate beneficiary premiums..." Let's write this finding. It will be incredibly comprehensive and provide a massive update on this crucial regulatory and commercial intersection. Let's make sure the slug is exactly `oral-obesity-pills-approved-medicare-glp1-bridge`. Let's invoke `write_note`.

I will write a detailed research note updating the previous finding on oral obesity pills and the Medicare GLP-1 Bridge program (slug: `oral-obesity-pills-approved-medicare-glp1-bridge`) to reflect the latest May 2026 regulatory changes, clinical approvals, and the major CMS program extension.

I will now write a new finding on the competitive clinical pipeline, highlighting the latest Phase 2 results for Viking Therapeutics' oral VK2735 (presented at ECO 2026 on May 12, 2026) and Roche's subcutaneous CT-388 (announced in January 2026). This will give investors critical details on the top late-stage challengers to Eli Lilly and Novo Nordisk. Let's call it `glp1-competitive-pipeline-viking-roche-updates`.

I will now write a finding on the impact of the GLP-1 boom on medical devices, specifically focusing on the decline of bariatric surgery, using the concrete statistics from the Mass General Brigham / Harvard study. This directly addresses the topic brief's requirement to track "impact on medical device companies like bariatric surgery and diabetes monitoring." Let's call it `glp1-bariatric-surgery-decline-device-impact`.

I will now write a comprehensive research summary note for this cycle (May 24, 2026), synthesizing the clinical, regulatory, and device impacts we have researched. Let's call it `cycle-summary-2026-05-24`.

I will now resolve the open thread `019e53de-db5a-77a8-b3d2-d534444016e5` regarding the Medicare GLP-1 Bridge program launch and patient volumes, as this cycle has uncovered major, critical updates: the program has been officially extended through Dec 31, 2027, and the BALANCE model has been delayed. I will also open a new follow-up thread to track the actual launch and patient volume of this program once it goes live on July 1, 2026. Let's resolve the current thread first.

I will now record a new follow-up thread to track the actual operational rollout, pharmacy claims volume, and patient uptake of the Medicare GLP-1 Bridge program once it launches on July 1, 2026, and throughout its extended run to 2027. This ensures future research cycles continue to track this critical program.

I will now call `finish_cycle` to complete this research cycle, as all findings have been successfully written and the threads have been updated and resolved.

Completed the research cycle on the GLP-1 drug boom and its ripple effects. I tracked major clinical approvals, competitive pipelines, federal Medicare policy changes, and impacts on surgical devices, resolving the existing thread and opening a follow-up thread for the July 1, 2026 launch. Detailed findings and summaries have been written to the notes.